Author(s)

Tania Robyn Chase, Kai Elliot Cham, Bill Elliot Cham

Australasian Medical Research, Port Vila, Republic of Vanuatu.

Basal cell carcinoma is the most common form of skin cancer and the most frequently occurring form of all cancers. Conventional treatments to remove or destroy basal cell carcinoma are indiscriminate and also remove or destroy normal skin cells resulting in compromised cosmetic outcomes. Consequences of these treatments include body-image issues, anxiety, post-traumatic stress disorder, depression, and poorer quality of social and family life. A progressive topical cream formulation, Curaderm, containing the natural BEC glycoalkaloids, have shown to have advantages over conventional treatments. However, comprehensive clinical features of the skin cancer lesions during treatment with Curaderm have to date not been reported. This report shows that using unpublished data from a large number of patients with varying sizes, types and locations of basal cell carcinomas when treated with Curaderm in a phase 3 trial, an initial increase in size of the lesions occur, followed by a reverse course, leading to complete removal of the skin cancer. The specificity and mode of action of Curaderm explains the superior cosmetic outcomes when compared with conventional therapies.

Curaderm, Skin Cancer, Basal Cell Carcinoma, BEC, Glycoalkaloids, Conventional Treatments

Chase, T. , Cham, K. and Cham, B. (2024) Unique Clinical Features of Curaderm when Treating Skin Cancers. Journal of Cancer Therapy, 15, 13-27. doi: 10.4236/jct.2024.151002.